Status:
COMPLETED
Study of Milnacipran for the Treatment of Fibromyalgia
Lead Sponsor:
Forest Laboratories
Conditions:
Fibromyalgia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine i...
Eligibility Criteria
Inclusion
- Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria
Exclusion
- Psychiatric illness
- Depression
- Suicidal risk
- Substance abuse
- Pulmonary dysfunction
- Renal impairment
- Active cardiac disease
- Liver disease
- Autoimmune disease
- Cancer
- Sleep apnea
- Inflammatory bowel disease
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT00098124
Start Date
November 1 2004
End Date
December 1 2006
Last Update
December 24 2007
Active Locations (80)
Enter a location and click search to find clinical trials sorted by distance.
1
Forest Investigative Site
Birmingham, Alabama, United States, 35205
2
Forest Investigative Site
Mobile, Alabama, United States, 36608
3
Forest Investigative Site
Montgomery, Alabama, United States, 36111
4
Forest Investigative Site
Peoria, Arizona, United States, 85381